Synthetic Lethality of Metabolic Enzymes
Four terms, one of which is a pair
| Term | Definition | Minimum design |
|---|---|---|
| Synthetic lethal | Single perturbation viable in both states; both together lethal | Two states × two perturbations |
| Synthetic sick | Same, but reduced fitness rather than death | Same design, graded readout |
| Sensitisation | One perturbation increases the effect of another | One state, two doses |
| Conditional dependency | Requirement appears only under a condition (genotype, nutrient, drug) | Two conditions, one perturbation |
Only the first two require the two-by-two. The third and fourth are frequently published as the first, and they are different claims with different biomarker implications: a sensitiser needs a combination strategy; a synthetic lethal needs a genotype-defined population.
Important distinction. "Gene X is essential in MTAP-deleted cells" is a conditional dependency. "Gene X deletion is lethal only when MTAP is also deleted" is a synthetic lethal interaction. The first is compatible with X being essential in both states to different degrees; the second is not.
Why metabolic synthetic lethality is usually conditional
Metabolic enzymes sit in networks with alternative inputs. Whether removing an enzyme is lethal therefore depends on what else is supplied.
| Supply route | Effect on the apparent interaction |
|---|---|
| Salvage pathway present | De novo synthesis is dispensable regardless of genotype |
| Nutrient in medium or diet | The dependency disappears when the nutrient is available |
| Redundant isozyme | Single knockout shows nothing |
| Compensatory flux through a parallel pathway | Effect is partial and time-dependent |
| Transport | The cell cannot use an alternative substrate that is present |
This is why metabolic synthetic lethality screens find interactions that fail to reproduce in vivo: the interaction was real in the medium and absent in the plasma. The disease pillar makes the same point about dependency generally; for synthetic lethality the consequence is sharper, because the interaction is the product.
The canonical example, and what it teaches
MTAP is frequently co-deleted with CDKN2A. Loss of MTAP causes accumulation of methylthioadenosine (MTA), which partially inhibits PRMT5; the cell survives by a narrow margin. Inhibiting MAT2A reduces S-adenosylmethionine availability and collapses that margin, producing PRMT5-dependent lethality.
| Element | What it demonstrates |
|---|---|
| Genotype as biomarker | The deletion is the selection criterion, measurable before treatment |
| A metabolic axis, not a single enzyme | MTAP–MTA–MAT2A–SAM–PRMT5 |
| A narrow margin, not an absent pathway | The cell is viable; the interaction exploits the margin |
| Two directions of evidence | Genetic (MAT2A knockout) and pharmacological (MAT2A inhibitor) |
The teaching point is the third row. Most metabolic synthetic lethals are not "pathway present versus absent" but "margin wide versus narrow". That has two consequences: the effect is graded rather than binary, and it is sensitive to anything else that shifts the margin.
Evidence standard
| Level | Experiment | What it establishes |
|---|---|---|
| 1 | Panel of cell lines stratified by the genotype | Association between genotype and sensitivity |
| 2 | Isogenic pair (knockout and wild type in the same background) | The genotype causes the difference |
| 3 | Second perturbation (second guide, independent compound) | Not a reagent artefact |
| 4 | Rescue with the deleted gene or the downstream product | The mechanism |
| 5 | In vivo at achievable exposure | The interaction exists in a tissue |
Level 1 alone is the most common and the weakest: a panel correlation is confounded by everything else that differs between lines, including the lineage in which the deletion typically occurs. Level 2 is what most published claims lack, and it is the cheapest of the five.
Caveat on isogenic pairs. An isogenic pair generated by CRISPR knockout of a passenger gene can carry clones with different proliferation rates, different karyotypes and different off-target edits. Two clones per state, plus a second guide, is the minimum that separates the genotype from the clone.
The asymmetry problem
A synthetic lethal pair is symmetric in principle and asymmetric in practice: one gene is the biomarker, the other is the drug target. Getting the direction wrong produces a programme that tests the wrong thing.
| Direction | Question | Decision |
|---|---|---|
| Target the deleted gene | Usually impossible — it is already absent | Not a target |
| Target the partner | Exploit the margin created by the deletion | The usual strategy |
| Target a downstream node | PRMT5 in the MTAP case | Wider effect, narrower window |
Important distinction. The biomarker is usually a loss-of-function event, and loss-of-function biomarkers are harder to assay than amplifications or mutations. A deletion call at the boundary between homozygous and heterozygous loss is exactly where the eligible population is decided, and it is the least reproducible measurement in the workflow.
Failure modes
- • One-arm screen described as a synthetic lethality screen. It finds dependencies, not interactions.
- • Interaction measured only in complete medium. The nutrient removed the requirement.
- • Panel correlation without an isogenic test. Confounded by lineage.
- • Compound-only evidence. Off-target effects in a chemotype that also inhibits a parallel enzyme.
- • Effect reported as binary. Most metabolic interactions are graded; the effect size and its confidence interval are the result.
- • Biomarker assay not validated at the cut-off. The eligible population is defined by the least reliable step.
Where this connects
- • Tumour metabolic dependency article supplies the four-gate target validation sequence this evidence standard supports.
- • Amino acid pillar supplies the one-carbon and methionine cycle logic behind the MTAP–MAT2A axis.
- • Disease pillar supplies the environment frame: dependency and interaction are both properties of a medium and a tissue.
- • Operationally, library choice, coverage and scoring for the screen itself are in the companion article on designing a synthetic lethality screen.
Scientific interpretation and experimental design
- • A synthetic lethal interaction needs two arms. Design for the pair or do not use the term.
- • Separate interaction from sensitisation. They imply different clinical strategies.
- • Metabolic interactions are conditional. Report the medium and the nutrient supply.
- • Isogenic pairs are the cheapest decisive test. Panel correlations are not.
- • Two clones, two guides. Clone-level artefacts are common.
- • The margin is the mechanism. Most metabolic interactions are graded.
- • Validate the biomarker at its cut-off. That is where enrolment is decided.
Selected references for further reading
- • Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nature Reviews Cancer. 2005;5:689–698.
- • Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351:1214–1218.
- • Mavrakis KJ, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351:1208–1213.
- • Oike T, et al. Molecular mechanisms of synthetic lethality and their application to cancer therapy. Cancer Science. 2017;108:1–11.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »